KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short term Debt: 2009-2025

Historic Short term Debt for Ionis Pharmaceuticals (IONS) over the last 14 years, with Sep 2025 value amounting to $630.9 million.

  • Ionis Pharmaceuticals' Short term Debt rose 1318.83% to $630.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.9 million, marking a year-over-year increase of 1318.83%. This contributed to the annual value of $44.3 million for FY2023, which is N/A change from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Short term Debt stood at $630.9 million, which was up 0.13% from $630.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Short term Debt's 5-year high stood at $630.9 million during Q3 2025, with a 5-year trough of $3.5 million in Q4 2021.
  • Moreover, its 3-year median value for Short term Debt was $44.4 million (2024), whereas its average is $239.8 million.
  • Examining YoY changes over the last 5 years, Ionis Pharmaceuticals' Short term Debt showed a top increase of 1,389.54% in 2021 and a maximum decrease of 98.86% in 2021.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Short term Debt stood at $3.5 million in 2021, then tumbled by 91.98% to $5.0 million in 2022, then reached $44.3 million in 2023, then reached $44.5 million in 2024, then surged by 1,318.83% to $630.9 million in 2025.
  • Its Short term Debt stands at $630.9 million for Q3 2025, versus $630.1 million for Q2 2025 and $44.5 million for Q3 2024.